



# Provider Bulletin



May 26, 2021

This Provider Bulletin applies to the lines of business and provider types checked below:

PHP (Medicare)  Primary Care Physicians  Specialists  
 PHC California (Medicaid)  Hospitals  Ancillary  AHF Grants (Ryan White)

## Pharmacy Approved-CABENUVA

As an on-going effort to improve and enhance benefits, PHP has approved CABENUVA (*cabotegravir/rilpivirine extended-release injectable suspension*) under Part D benefits for PHP beneficiaries.

**CABENUVA** is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

### Please note Clinical Considerations:

- Prior Authorization not required.
- Patients will need to be virally suppressed on an oral regimen prior to start.
- A 30-day oral lead-in dose of cabotegravir plus Edurant (rilpivirine) will be required (*two tablets once daily*).
- Co-packaged oral cabotegravir plus rilpivirine is expected to be available via a limited distribution from ViiV.
- The Cabenuva loading dose requires two 3 mL IM injections (*600 mg cabotegravir plus 900 mg rilpivirine*).
- Maintenance dosing, involving two 2 mL IM injections (*400 mg cabotegravir plus 600 mg rilpivirine*), will be required every four weeks (*+/- 1 week*).
- Cabenuva requires cold-chain storage or a temperature-controlled supply chain and will need to be brought to room temperature before administration.
- The recommended injection procedure is intramuscular administration using the Z-track method in the gluteus medius, and generally will require administration in a clinic or possibly a pharmacy in a private space.

For instructions on obtaining the oral lead-in regimen, please visit <https://www.cabenuva.com/> or work with your local pharmacy.

This Provider Bulletin is not intended to replace or conflict with any requirements outlined in your signed Agreement with AHF or PHP. If you have any questions contact the Provider Relations Department. Florida providers please email Provider Relations Department [FLPR@phcplans.org](mailto:FLPR@phcplans.org). California providers please email the California Provider Relations Department at [CAPR@aidshhealth.org](mailto:CAPR@aidshhealth.org). Georgia providers please email [GAPR@positivehealthcare.org](mailto:GAPR@positivehealthcare.org).